Detalles de la búsqueda
1.
Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer.
Clin Exp Pharmacol Physiol
; 44(1): 88-93, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27716993
2.
[Clinical efficacy and safety of trastuzumab plus capecitabine as first-line therapy for HER-2 positive metastatic breast cancer].
Zhonghua Yi Xue Za Zhi
; 95(34): 2796-8, 2015 Sep 08.
Artículo
en Zh
| MEDLINE | ID: mdl-26711981
3.
[PTEN loss correlates withthe clinical efficacy of lapatinib in HER2 positive metastatic breast cancer with trastuzumab-resistance].
Zhonghua Yi Xue Za Zhi
; 95(28): 2264-7, 2015 Jul 28.
Artículo
en Zh
| MEDLINE | ID: mdl-26710948
4.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
Lancet
; 382(9897): 1021-8, 2013 Sep 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-23871490
5.
Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.
Anticancer Drugs
; 25(10): 1175-81, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25089570
6.
[Clinical observations of ductal carcinoma in situ and early stage breast cancer with invasive depth less than 1 cm].
Zhonghua Yi Xue Za Zhi
; 94(4): 269-72, 2014 Jan 28.
Artículo
en Zh
| MEDLINE | ID: mdl-24731492
7.
[Serum HER2 ECD level and its clinical significance in advanced breast cancer patients with different molecular subtypes].
Zhonghua Yi Xue Za Zhi
; 94(18): 1384-7, 2014 May 13.
Artículo
en Zh
| MEDLINE | ID: mdl-25142988
8.
[Detection of circulating tumor cells and its clinical value for different stages and various subtypes of breast cancer].
Zhonghua Yi Xue Za Zhi
; 94(36): 2812-5, 2014 Sep 30.
Artículo
en Zh
| MEDLINE | ID: mdl-25534097
9.
[Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
Zhonghua Zhong Liu Za Zhi
; 35(1): 38-42, 2013 Jan.
Artículo
en Zh
| MEDLINE | ID: mdl-23648298
10.
[Clinical observation of sunitinib treatment for refractory advanced breast cancer ulcer].
Zhonghua Yi Xue Za Zhi
; 93(2): 96-8, 2013 Jan 08.
Artículo
en Zh
| MEDLINE | ID: mdl-23648343
11.
[Efficacy and prognostic analysis of retreatment with trastuzumab-based therapy after multi-line targeted therapy resistance in HER2-positive metastatic breast cancer].
Zhonghua Yi Xue Za Zhi
; 93(1): 48-52, 2013 Jan 01.
Artículo
en Zh
| MEDLINE | ID: mdl-23578455
12.
Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Anticancer Drugs
; 23(7): 718-23, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22739713
13.
Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy.
Support Care Cancer
; 20(8): 1875-84, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22041866
14.
[A clinical study of reasonable doses of docetaxel salvage therapy for patients with metastatic breast cancer].
Zhonghua Zhong Liu Za Zhi
; 34(10): 764-9, 2012 Oct.
Artículo
en Zh
| MEDLINE | ID: mdl-23291071
15.
[Analysis of chemotherapeutic efficacies in metastatic triple-negative breast cancer].
Zhonghua Yi Xue Za Zhi
; 92(42): 3001-3, 2012 Nov 13.
Artículo
en Zh
| MEDLINE | ID: mdl-23328295
16.
[Chinese HER2 positive early breast cancer trastuzumab adjuvant therapy: preliminary outcomes].
Zhonghua Yi Xue Za Zhi
; 92(47): 3345-9, 2012 Dec 18.
Artículo
en Zh
| MEDLINE | ID: mdl-23328596
17.
Evaluation of treatment response for breast cancer: are we entering the era of "biological complete remission"?
Chin J Cancer Res
; 24(4): 403-7, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23359646
18.
Gene expression profiling for breast cancer prognosis in Chinese populations.
Breast J
; 17(2): 172-9, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21410584
19.
[Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
Zhonghua Zhong Liu Za Zhi
; 33(11): 850-3, 2011 Nov.
Artículo
en Zh
| MEDLINE | ID: mdl-22335952
20.
Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment.
Pharm Biol
; 49(11): 1167-72, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22014264